Somatic HER2 mutations may also have a role to play in neratinib resistance, with acquisition of a T798I gatekeeper mutation recently being reported in a neratinib-treated patient with ER+/HER2-mutant (L869R) breast cancer [78]. This evidence concerns the gene ERBB2 and breast carcinoma.